

# HEDIS® Tips:

## Medication Management for People with Asthma (MMA)

### MEASURE DESCRIPTION

The percentage of patients 5–64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period. Two rates are reported:

1. The percentage of patients who remained on an asthma controller medication for at least 50% of their treatment period.
2. The percentage of patients who remained on an asthma controller medication for at least 75% of their treatment period.

Patients are in the measure if they met at least one of the following during both the measurement year and the year prior.

- At least one ED visit with asthma as the principal diagnosis.
- At least one acute inpatient claim/encounter, with asthma as the principal diagnosis without telehealth.
- At least one acute inpatient discharge with a principal diagnosis of asthma.
- At least 4 outpatient, observation visits, telephone visits or online assessments on different dates of service, with any diagnosis of asthma **and** at least 2 asthma medication dispensing events for any controller or reliever medication. Only 3 of the 4 visits may be an outpatient telehealth visit, telephone visit, or an online assessment. Telehealth must be identified with a telehealth modifier or telehealth POS code.
- At least 4 asthma medication dispensing events for any controller medication or reliever medication.

### CODES INCLUDED IN THE CURRENT HEDIS MEASURE

#### Codes to Identify Asthma

Description	ICD-10 Codes
Mild Intermittent Asthma	J45.20, J45.21, J45.22
Mild Persistent Asthma	J45.30, J45.31, J45.32
Moderate Persistent Asthma	J45.40, J45.41, J45.42
Severe Persistent Asthma	J45.50, J45.51, J45.52
Other and Unspecified Asthma	J45.901, J45.902, J45.909, J45.990, J45.991, J45.998

#### Asthma Medications

Asthma Controller Medications	Prescriptions
Antiasthmatic combinations	Dyphylline-guaifenesin,
Anti-interleukin-5	Mepolizumab, Reslizumab, Benralizumab
Antibody inhibitor	Omalizumab
Inhaled steroid combinations	Budesonide-formoterol, Fluticasone-salmeterol, Fluticasone-vilanterol, Formoterol-mometasone
Inhaled corticosteroids	Beclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone, Mometasone
Leukotriene modifiers	Montelukast, Zafirlukast, Zileuton
Methylxanthines	Theophylline
Asthma Reliever Medications	Prescriptions
Short-acting, inhaled beta-2 agonists	Albuterol, Levalbuterol

\*Please refer to the Molina Healthcare Drug Formulary at [www.molinahealthcare.com](http://www.molinahealthcare.com) for asthma controller medications that may require prior authorization or step therapy.

#### Codes to Identify Telephone and Telehealth Appointments

Description	Codes
Telephone Visits	CPT®: 98966, 98967, 98968, 99441, 99442, 99443
Telehealth Modifier	95, GT
	WITH POS: 02

### HOW TO IMPROVE HEDIS SCORES

- ☐ Ensure proper coding to avoid coding asthma if not formally diagnosing asthma and only asthma-like symptoms were present. Ex: wheezing during viral URI and acute bronchitis is not “asthma.”
- ☐ Educate patients on use of asthma medications and importance of using asthma controller medications daily.
- ☐ Prescribe a long-term controller medication and provide reminders to your patients to fill controller medications.
- ☐ Remind Molina patients mail-order delivery is available
- ☐ Refer patients for health management interventions and coaching by contacting Health Care Services at Molina Healthcare.
- ☐ Schedule telephone and/or telehealth appointments to diagnose patients with asthma and prescribe a controller medication. Only three of the four outpatient visits may be a telehealth visit, a telephone visit or an online assessment.

The information presented herein is for informational and illustrative purposes only. It is not intended, nor is it to be used, to define a standard of care or otherwise substitute for informed medical evaluation, diagnosis and treatment which can be performed by a qualified medical professional. Molina Healthcare Inc. does not warrant or represent that the information contained herein is accurate or free from defects.

All summaries of the measures contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Updated 6/19/2020